News releases - Merck.com
WEB6 days ago · Merck Provides Update on Phase 3 KEYNOTE-867 and KEYNOTE-630 Trials. August 27, 2024. Merck Announces Phase 3 Trial Initiation for Bomedemstat, an Investigational Candidate for the Treatment of Certain Patients With Essential Thrombocythemia. August 26, 2024.
Merck wins first FDA approval for Keytruda as a treatment for ...
WEB2 days ago · Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a treatment for malignant plural mesothelioma, a rare cancer...
Patritumab Deruxtecan Demonstrated Statistically Significant ... - Merck
WEB3 days ago · Daiichi Sankyo and Merck’s patritumab deruxtecan demonstrates a statistically significant progression-free survival improvement in this EGFR-mutated non-small cell lung cancer population with high unmet need following prior EGFR TKI treatment. Discussions with global regulatory authorities to be initiated.
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and ... - Merck
WEB5 days ago · RAHWAY, N.J.-- (BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first-time presentation of overall survival (OS) results from the Phase 3 KEYNOTE-522 trial evaluating KEYTRUDA ® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with chemotherapy as pre-operative (neoadjuvant)...
Merck (MRK) earnings Q2 2024 - CNBC
WEBJul 30, 2024 · Merck on Tuesday reported second-quarter revenue and adjusted earnings that topped Wall Street's expectations as it saw strong sales from its blockbuster cancer drug Keytruda as well as other...
Merck's Keytruda Obtains its First FDA Approval for Mesothelioma
WEB1 day ago · Merck & Co., Inc. MRK announced that the FDA had approved its blockbuster anti-PD-1 therapy, Keytruda (pembrolizumab), for a new indication.
Merck Gets European Panel Backing for Keytruda in Two …
WEB16 hours ago · Merck & Co. said a European Medicines Agency panel recommended expanded approval of the drugmaker's blockbuster cancer treatment Keytruda in two types of gynecologic cancers.
Merck Announces Fourth-Quarter and Full-Year 2023 Financial …
WEBFeb 1, 2024 · Initiated More Than 20 Phase 3 Study Starts, Including the Progression of Eight Novel Assets Into Phase 3 in 2023. Augmented Pipeline Through Acquisitions of Prometheus and Imago, and Collaboration Agreements With Daiichi Sankyo and Kelun-Biotech in 2023. Full-Year 2024 Financial Outlook.
Merck & Co., Inc. (MRK) Latest Stock News & Headlines
WEBGet the latest Merck & Co., Inc. (MRK) stock news and headlines to help you in your trading and investing decisions.
Merck's wins FDA approval for Keytruda in combination
WEB2 days ago · Merck & Co. Inc. (MRK) said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda in combination with pemetrexed and platinum chemotherapy as a...